The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.

The bladder cancer market is poised for transformative growth between 2025 and 2035, driven by rising global incidence rates, ...

Among patients with suspected MIBC, the incorporation of mpMRI for initial staging prior to transurethral resection of ...

What About to Decrease Frequency of Cystoscopy? Joan Palou MD, Ph.D., Eva Comperat, MD, Ph.D., and Tahlita Zuiverloon, MD, Ph.D. Joan Palou, Eva Comperat, and Tahlita Zuiverloon debated the role of ...

Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 128.6 million in the fourth quarter of 2024 (Q4 2023: NOK ...

[6] The mainstay of diagnosis is the identification malignant cells in urine specimens and direct visualization of the bladder mucosa with cystoscopy and resection of the tumor if identified.

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...

Photocure ASA ( ($PHCUF) ) has shared an announcement. Photocure ASA reported a strong financial performance for the fourth quarter of 2024, with ...

Tommy was diagnosed with bladder cancer just before his 60th birthday. Now, thanks to a Cancer Research UK trial, he’s enjoying playing ...